Stem Cell Derived Extracellular Vesicle Therapy for Multiple Sclerosis, A Systematic Review and Meta-Analysis of Preclinical Studies
Stem Cells Translational Medicine · 2024
DOI: 10.1093/stcltm/szae011 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Stem Cells Translational Medicine, 2024. Verfasst von Mehri Barabadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Ritchie Centre, Hudson Institute of Medical Research, Victoria, Australia. Hauptthemen laut MEDLINE: Multiple Sclerosis, Extracellular Vesicles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Australian Postgraduate Research Training Program Scholarship.
Abstract (Originalsprache)
Stem cell therapy holds promise for multiple sclerosis (MS), with efficacy of different stem cell types reported across a range of preclinical MS animal models. While stem cell therapy has been approved for a small number of diseases in humans, extracellular vesicles (EVs) may provide an efficacious, cost-effective, and safer alternative to stem cell therapy. To this end, we conducted a systematic review with meta-analysis to assess the effectiveness of stem cell-derived secretome (EV and conditioned media (CM)) in animal models of MS. The data were extracted to calculate standardized mean differences for primary outcome measure of disease severity, using a random effect model. Additionally, several subgroup analyses were conducted to assess the impact of various study variables such as stem cell type and source, stem cell modification, route and time of administration, number of animals and animal’s age, and EV isolation methods on secondary outcome. Publication quality and risk of bias were assessed. Overall, 19 preclinical studies were included in the meta-analysis where stem cell EV/CM was found to significantly reduce disease severity in EV-treated (SMD = 2, 95% CI: 1.18-2.83, P < .00001) and CM-treated animals (SMD = 2.58, 95% CI: 1.34-3.83, P < .00001) compared with controls. Our analysis indicated that stem cell secretome has a positive effect on reducing demyelination, systemic neuroinflammation, and disease severity in preclinical models of MS. These findings indicate a potential therapeutic effect that merits investigation and validation in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Ritchie Centre, Hudson Institute of Medical Research, Victoria, Australia.
- Department of Obstetrics and Gynaecology, Monash University, Victoria, Australia.
- Cerebral Palsy Alliance Research Institute, Speciality of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia.
- Department of Paediatrics, Monash University, Victoria, Australia.
- Australian Regenerative Medicine Institute, Monash University, Victoria, Australia.
ORCID-Profile: Mehri Barabadi, Naveen Kumar
Förderung
- National Health and Medical Research Council
- Australian Postgraduate Research Training Program Scholarship
Zitieren
APA
Barabadi, M., Paton, M. C. B., Kumar, N., Lim, R., & Payne, N. L. (2024). Stem Cell Derived Extracellular Vesicle Therapy for Multiple Sclerosis, A Systematic Review and Meta-Analysis of Preclinical Studies. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szae011
Vancouver
Barabadi M, Paton MCB, Kumar N, Lim R, Payne NL. Stem Cell Derived Extracellular Vesicle Therapy for Multiple Sclerosis, A Systematic Review and Meta-Analysis of Preclinical Studies. Stem Cells Translational Medicine. 2024. doi:10.1093/stcltm/szae011
BibTeX
@article{Barabadi2024,
author = {Barabadi, Mehri and Paton, Madison C B and Kumar, Naveen and Lim, Rebecca and Payne, Natalie L},
title = {Stem Cell Derived Extracellular Vesicle Therapy for Multiple Sclerosis, A Systematic Review and Meta-Analysis of Preclinical Studies},
journal = {Stem Cells Translational Medicine},
year = {2024},
doi = {10.1093/stcltm/szae011}
}
EUVIMED